Gadolinium-based contrast agents used in MRI scans have been linked to a number of adverse side effects, most notably nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy.

Nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy are actually the same condition. When first described in medical literature in 2000, researchers and physicians gave the condition the name “nephrogenic fibrosing dermopathy” because initial observations noted the fibrosing effect only on the skin. The name was changed when evidence showed the malady also affected internal organs, muscles, and tendons. Nephrogenic systemic fibrosis reflects that new understanding of the disease’s effect on the entire system.

Nephrogenic systemic fibrosis has been linked to gadolinium-based contrast agents. The condition appears to only occur in patients with some form of kidney disease. The term “nephrogenic” means beginning with the kidney. Researchers have theorized that the increasing number of cases of NSF has to do with increased use of gadolinium-based contrast agents in renal disease patients. Experts now recommend tests that screen for kidney disease in those about to undergo MRI.

If you have developed NSF after being exposed to a gadolinium-based contrast agent, please contact the NSF Attorneys of Williams Kherkher by calling 800-761-3187.

Nephrogenic fibrosing dermopathy is a rare syndrome thatinvolves the hardening of skin and internal organs.

Nephrogenic fibrosing dermopathy was first identified in1997. The condition was not described as an independent disease entity untilthe year 2000. The sydrome’s affect on the skin is the most apparent, which ledto the name nephrogenic fibrosing dermopathy.

The condition was later found to affect any organ and thename was changed to nephrogenic systemic fibrosis.

In 2006, nephrogenic systemic fibrosis was linked to mricontrast agents containing gadolinium. The United States Food and DrugAdministration acknowledge this link in 2009 when the agency issued a black boxwarning for all gadolinium-based contrast agents.

If you have developed nephrogenic systemic fibrosis afterbeing administered a gadolinium-based contrast agent, please contact a gadolinium attorney of Williams Kherkher by calling 800-761-3187.

Nephrogenic fibrosing dermopathy is a disease seemingly occurring exclusively in patients with kidney disease which has been linked to gadolinium-based MRI contrast agents.

Nephrogenic fibrosing dermopathy may resemble skin diseases like scleroderma and scleromyxedema with thickening pigmentation developing on large areas of skin. The disease can also affect internal organs and cause shortening of muscles and tendons as well as scar tissue.

Skin biopsies are used to diagnose nephrogenic fibrosing dermopathy. Diagnosing the disease during its early stage may help slow the progression of the illness. 

If you have developed NSF of NFD because of gadolinium-based agents, you may be eligible for compensation. Contact a gadolinium lawyer of Williams Kherkher by calling 800-761-3187.

Over the past several years, researchers have found a correlation between the development of Nephrogenic Systemic Fibrosis and the increasing use of gadolinium-based MRI contrast agents.

Gadolinium, an element of the lanthanide series, is the chief component of virtually all contrast agents administered for magnetic resonance imaging. It has been linked to the development of Nephrogenic Systemic Fibrosis, formerly known as Nephrogenic Fibrosing Dermopathy. Nephrogenic Systemic Fibrosis is a systemic disorder with its most visible effects on the skin. NSF patients experience swelling and tightening of the skin.

The skin changes may begin as reddened or darkened patches or papules. Patients may experience burning, itching, or severe sharp pains in areas of involvement. 

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

A woman in Boston is suing a hospital after she claims an MRI contrasting agent she was given put her at risk for the Nephrogenic Systemic Fibrosis she contracted.

According to the lawsuit, 70 year-old Silvia DeSilva contracted Nephrogenic Systemic Fibrosis from gadolinium after being given the MRI contrasting agent at King Edward VII Memorial Hospital and Brighan Women's Hospital in Boston. Doctors administered the agent in 2007 in order to obtain better scan results.

According to her husband, 75 year-old Allan DeSilva, the doctors knew the risk of contracting her disfiguring, painful, and possibly fatal condition. 

The disease is known to occur after individuals with impaired kidney functions are exposed to a gadolinium-based contrasting agent.

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

After a 2007 MRI scan, a 70-year-old dialysis patient is planning to sue a Boston hospital after developing nephrogenic systemic fibrosis, or NSF.

The gadolinium-based agent improves and clarifies MRI scans. However, for patients with kidney issues, namely those on dialysis, the risk of developing NSF is increased to dangerous levels. The Food & Drug Administration has given the scanning agent their black box label, the highest warning the agency issues for potentially dangerous drugs. 

The woman was given the agent to improve her MRI scans at King Edward VII Memorial Hospital and Brighan and Women's Hospital in Boston in 2007. Since then, the woman has contracted the skin disorder. Her husband believes that the hospital staff and doctors should have known not to use gadolinium-based agents, especially considering the FDA's strict warnings especially directed to patients with kidney problems.

The hospital announced that it will try to reconcile grievances between the medical staff and family.

There is currently no cure or successful treatment for NSF.

If you have suffered adverse side-effects due to gadolinium-based agents, you may be eligible for compensation. Contact the nephrogenic systemic fibrosis attorneys of Williams Kherkher by calling 800-761-3187 today to discuss your claim.